Duration of Tamiflu in Severe Influenza A Pneumonia

Standard vs. Extended Duration

The Infectious Diseases Society of America recommends extending oseltamivir treatment beyond the standard 5-day course for severe influenza A pneumonia requiring hospitalization, with treatment duration guided by clinical response and evidence of persistent viral replication, particularly in critically ill patients 1
The standard duration of oseltamivir treatment for uncomplicated influenza is 5 days, which applies to otherwise healthy outpatients with mild disease, as recommended by the American Academy of Pediatrics and the American Family Physician 2, 3

Influenza viral replication is often protracted in severely ill patients, particularly those with immunocompromising conditions or requiring ICU admission, according to the Infectious Diseases Society of America 1
The Centers for Disease Control and Prevention indicate that antiviral treatment may be effective in reducing morbidity and mortality even when initiated >48 hours after illness onset in hospitalized patients 4

The Infectious Diseases Society of America considers extended duration (7-10+ days) for patients with documented or suspected immunocompromising conditions, severe pneumonia requiring ICU admission, ARDS or respiratory failure, or evidence of persistent viral replication after 7-10 days 1, 4

The Infectious Diseases Society of America recommends a standard dose of 75 mg twice daily for most hospitalized patients, and explicitly states not to routinely use higher doses of FDA-approved neuraminidase inhibitors for seasonal influenza 1
The Centers for Disease Control and Prevention suggested doubling the dose (150 mg twice daily) for severely ill patients in 2011, but the Infectious Diseases Society of America recommends against routine use of higher doses in their 2019 guidelines 1, 4

The Infectious Diseases Society of America recommends starting oseltamivir immediately upon suspicion of severe influenza pneumonia, regardless of time since symptom onset, and beginning with 75 mg twice daily (standard FDA-approved dose) 1, 4
The Centers for Disease Control and Prevention and the Infectious Diseases Society of America recommend initiating treatment even if >48 hours from symptom onset in hospitalized patients, and continuing treatment based on clinical response and evidence of persistent viral replication 1, 4

The Infectious Diseases Society of America and the Centers for Disease Control and Prevention recommend not withholding treatment in hospitalized patients simply because >48 hours have elapsed since symptom onset, and not automatically stopping at 5 days in critically ill patients 1, 4
The Infectious Diseases Society of America recommends not routinely doubling the dose despite some conflicting data, and not forgetting to investigate bacterial coinfection in patients with severe initial presentation or those who deteriorate after initial improvement 1